Dr Martens reported a 61% increase in adjusted pre-tax profit to £55 million for the year ending March 29, despite a 2.9% revenue decline to £764.9 million. The company improved gross margins to 66.2% by reducing discounting and focusing on higher-quality sales, with shoes driving 19% sales growth. Boots sales stabilized, and bags showed promising early growth. Led by CEO Ije Nwokorie, the brand is shifting to a consumer-first strategy, aiming for strong profit growth in the 2027 financial year despite global uncertainties.
U-BX Technology's stock fell 15.6% in after-hours trading following the announcement of a 1-for-25 reverse stock split effective Friday. The move will reduce the number of outstanding shares significantly to maintain Nasdaq listing compliance. The co...
Empire Metals Ltd has signed a definitive agreement to sell its 75% stake in the Eclipse Mining Lease near Kalgoorlie, Western Australia, for A$750,000. The sale includes a non-refundable deposit of A$50,000 already received, with the remaining A$700...
The surge in memory chip prices, driven by hyperscaler capital expenditure, reflects a shift from component shortages to pricing power in AI infrastructure. Now, the main bottleneck is moving from chip and memory availability to physical site enablem...
Bitcoin fell below $77,000 after four days of losses, pressured by Iran's new "Hormuz Safe" system requiring $2 million in Bitcoin for Strait of Hormuz passage and over $1 billion withdrawn from crypto funds last week. Rising oil prices and inflation...
Coiled Therapeutics, a clinical-stage oncology company, has begun trading on the US OTCQB Venture Market under the ticker COTXF, allowing US investors to buy shares in dollars during US market hours. This move aims to improve liquidity and broaden it...
